electroCore, Inc. announced a peer-reviewed study showing their TAC-STIM device enhances mood, task performance, and learning in high-stress military training. Results from the study with 70 active-duty Air Force trainees showed tVNS users had reduced stress, improved energy, and enhanced performance compared to the control group. The study positions TAC-STIM as a transformative solution for military training and deployment, as well as for elite athletes and consumers interested in cognitive performance improvement.
The study involved 70 active-duty Air Force trainees randomly assigned to receive either tVNS or a sham device during the most intensive phase of Military Qualification Training. Results showed tVNS users reported reduced stress and distress, increased energy, and perceived skill improvements. Objective performance gains were demonstrated in intelligence tasks and mission execution, with lasting improvements in mood and resilience observed over four days.
TAC-STIM was purpose-built for active-duty use based on input from Special Operations units in the US Air Force and Army. The technology is positioned for entry into consumer wellness, workplace productivity, and educational markets. The benefits of tVNS/nVNS technology align with the demand for cognitive augmentation tools in civilian domains, from executive training to sports and healthcare.
For access to the final paper, visit the link provided. electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies. Their products, gammaCore and Quell, treat chronic pain syndromes, while Truvaga and TAC-STIM promote general wellness and human performance.
This press release contains forward-looking statements regarding the effectiveness of TAC-STIM for mood enhancement, task performance, and learning in high-stress military training environments. Factors such as product development, competition, and overall market conditions could impact actual results. Investors should consult all information provided and refer to the risk factor disclosure available at the SEC website. Contact ECOR Investor Relations for more information.
Read more at GlobeNewswire: TAC-STIM Demonstrates Significant Performance Improvements